pd 98059 has been researched along with 5-(alpha-methyl-4-bromobenzylamino)phosphonomethyl-1,4-dihydroquinoxaline-2,3-dione in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, Y; Feng, C; Xiao, L | 1 |
1 other study(ies) available for pd 98059 and 5-(alpha-methyl-4-bromobenzylamino)phosphonomethyl-1,4-dihydroquinoxaline-2,3-dione
| Article | Year |
|---|---|
Glucocorticoid rapidly enhances NMDA-evoked neurotoxicity by attenuating the NR2A-containing NMDA receptor-mediated ERK1/2 activation.
Topics: Animals; Blotting, Western; Calcium; Cells, Cultured; Enzyme Inhibitors; Flavonoids; Glucocorticoids; Hippocampus; Imidazoles; Mifepristone; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; N-Methylaspartate; Neurons; p38 Mitogen-Activated Protein Kinases; Pyridines; Quinoxalines; Rats; Rats, Sprague-Dawley; Receptors, N-Methyl-D-Aspartate | 2010 |